Michael Schömig

1.2k total citations
22 papers, 506 citations indexed

About

Michael Schömig is a scholar working on Nephrology, Hematology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Michael Schömig has authored 22 papers receiving a total of 506 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Nephrology, 6 papers in Hematology and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Michael Schömig's work include Dialysis and Renal Disease Management (8 papers), Erythropoietin and Anemia Treatment (6 papers) and Blood Pressure and Hypertension Studies (5 papers). Michael Schömig is often cited by papers focused on Dialysis and Renal Disease Management (8 papers), Erythropoietin and Anemia Treatment (6 papers) and Blood Pressure and Hypertension Studies (5 papers). Michael Schömig collaborates with scholars based in Germany, United Kingdom and Netherlands. Michael Schömig's co-authors include Eberhard Ritz, Michael Reusch, Jonathan Barratt, Udaya Valluri, Vedat Schwenger, Botond Csiky, Ralf Dikow, Władysław Sułowicz, Ciro Esposito and Branislav Andrić and has published in prestigious journals such as Kidney International, Journal of the American Society of Nephrology and Journal of Internal Medicine.

In The Last Decade

Michael Schömig

21 papers receiving 488 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Schömig Germany 11 267 253 79 65 64 22 506
Botond Csiky Hungary 11 645 2.4× 226 0.9× 78 1.0× 121 1.9× 47 0.7× 38 982
Thilo Krueger Germany 7 263 1.0× 111 0.4× 78 1.0× 58 0.9× 31 0.5× 8 641
Der‐Cherng Tarng Taiwan 11 234 0.9× 181 0.7× 72 0.9× 47 0.7× 14 0.2× 12 531
John Houghton United Kingdom 10 75 0.3× 109 0.4× 50 0.6× 53 0.8× 16 0.3× 26 389
Der-Cherng Tarng Taiwan 13 179 0.7× 78 0.3× 68 0.9× 77 1.2× 10 0.2× 17 469
Aliza M. Thompson United States 8 130 0.5× 146 0.6× 49 0.6× 56 0.9× 33 0.5× 14 374
Konstantin Gurevich United States 6 234 0.9× 156 0.6× 65 0.8× 45 0.7× 30 0.5× 8 399
Sylvie Opatrná Czechia 12 205 0.8× 180 0.7× 51 0.6× 59 0.9× 13 0.2× 27 420
Sabrina Paoletti Italy 14 392 1.5× 162 0.6× 51 0.6× 202 3.1× 11 0.2× 19 628
Charis Matsouka Greece 14 79 0.3× 623 2.5× 233 2.9× 44 0.7× 34 0.5× 37 932

Countries citing papers authored by Michael Schömig

Since Specialization
Citations

This map shows the geographic impact of Michael Schömig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schömig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schömig more than expected).

Fields of papers citing papers by Michael Schömig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schömig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schömig. The network helps show where Michael Schömig may publish in the future.

Co-authorship network of co-authors of Michael Schömig

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Schömig. A scholar is included among the top collaborators of Michael Schömig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Schömig. Michael Schömig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Topf, Joel Michels, Thomas D. Wooldridge, Michael Schömig, et al.. (2022). Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies. Kidney Medicine. 4(8). 100512–100512. 39 indexed citations
2.
Barratt, Jonathan, Władysław Sułowicz, Michael Schömig, et al.. (2021). Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Advances in Therapy. 38(10). 5345–5360. 50 indexed citations
3.
Csiky, Botond, Michael Schömig, Ciro Esposito, et al.. (2021). Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES). Advances in Therapy. 38(10). 5361–5380. 71 indexed citations
4.
Topf, Joel Michels, Warren Wen, Catherine Munera, Frédérique Menzaghi, & Michael Schömig. (2021). Efficacy of Difelikefalin in Subjects With Moderate-to-Severe Chronic Kidney Disease–Associated Pruritus: Pooled Subgroup Analysis of KALM-1 and KALM-2. SKIN The Journal of Cutaneous Medicine. 5(6). s77–s77. 1 indexed citations
5.
6.
Barratt, Jonathan, Branislav Andrić, Michael Schömig, et al.. (2020). MO001ROXADUSTAT FOR THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS: A PHASE 3, RANDOMISED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY. Nephrology Dialysis Transplantation. 35(Supplement_3). 2 indexed citations
7.
Dikow, Ralf, Vedat Schwenger, Michael Schömig, & Eberhard Ritz. (2002). How should we manage anaemia in patients with diabetes?. Nephrology Dialysis Transplantation. 17(suppl_1). 67–72. 75 indexed citations
8.
Orth, Stephan R., Michael Schömig, & E. Ritz. (2001). Pharmacological intervention in progressive renal diseases. Nephrology Dialysis Transplantation. 16(suppl 5). 19–25. 4 indexed citations
9.
Schömig, Michael, et al.. (2001). Controversy on optimal blood pressure on haemodialysis: normotensive blood pressure values are essential for survival. Nephrology Dialysis Transplantation. 16(3). 469–474. 23 indexed citations
10.
Ritz, Eberhard, Ivan Rychlík, Michael Schömig, & J. Wagner. (2001). Blood pressure in diabetic nephropathy - current controversies. Journal of Internal Medicine. 249(3). 215–223. 4 indexed citations
11.
Ritz, Eberhard, Ivan Rychlík, Michael Schömig, & J. Wagner. (2001). Blood pressure in diabetic nephropathy – current controversies. Journal of Internal Medicine. 249(3). 215–223.
12.
Ritz, Eberhard, Michael Schömig, & Jürgen Wagner. (2000). Counteracting progression of renal disease: A look into the future. Kidney International. 57. S71–S76. 7 indexed citations
13.
Schömig, Michael, et al.. (2000). The Microinflammatory State of Uremia. Blood Purification. 18(4). 327–332. 29 indexed citations
14.
Schömig, Michael & Eberhard Ritz. (2000). Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites. Nephrology Dialysis Transplantation. 15(suppl_5). 18–24. 16 indexed citations
15.
Schömig, Michael, Vedat Schwenger, & Eberhard Ritz. (2000). Circadian rhythm of blood pressure in renal disease. Current Hypertension Reports. 2(5). 490–494. 6 indexed citations
16.
Schömig, Michael & Eberhard Ritz. (2000). Management of disturbed calcium metabolism in uraemic patients: 3. Potential perspectives—calcimimetics*. Nephrology Dialysis Transplantation. 15(suppl_5). 30–31. 7 indexed citations
17.
Schömig, Michael & Eberhard Ritz. (2000). Cardiovascular problems in diabetic patients on renal replacement therapy. Nephrology Dialysis Transplantation. 15(suppl_5). 111–116. 8 indexed citations
18.
Ritz, Eberhard & Michael Schömig. (2000). The diabetic patient with renal failure.. PubMed. 20 Suppl 3. 16–24. 2 indexed citations
19.
Ritz, Eberhard, et al.. (1999). Osteodystrophy in the millennium. Kidney International. 56. S94–S98. 18 indexed citations
20.
Quaschning, Thomas, Michael Schömig, Markus A. Keller, et al.. (1999). Non-Insulin-Dependent Diabetes Mellitus and Hypertriglyceridemia Impair Lipoprotein Metabolism in Chronic Hemodialysis Patients. Journal of the American Society of Nephrology. 10(2). 332–341. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Botond Csiky Breakdown of academic impact, for papers by Thilo Krueger Breakdown of academic impact, for papers by Der‐Cherng Tarng Breakdown of academic impact, for papers by John Houghton Breakdown of academic impact, for papers by Der-Cherng Tarng Breakdown of academic impact, for papers by Aliza M. Thompson Breakdown of academic impact, for papers by Konstantin Gurevich Breakdown of academic impact, for papers by Sylvie Opatrná Breakdown of academic impact, for papers by Sabrina Paoletti Breakdown of academic impact, for papers by Charis Matsouka
Rankless by CCL
2026